Enzalutamide patent expiration date us?

When does enzalutamide’s U.S. patent protection end?

Enzalutamide (Xtandi) has multiple patents and exclusivity protections in the U.S., so the “expiration date” depends on which specific patent and exclusivity you mean (for example, the earliest patent expiring vs. later, narrower patents). DrugPatentWatch tracks this as a set of patent filings and projected expiry timelines rather than one single date for the whole product. [1]

What date should patients or researchers look for specifically?

Most people asking this question want the date when generic or biosimilar competition could become possible in the U.S. That timing generally aligns with when the relevant U.S. patents protecting the drug (and any associated exclusivities) expire, which can be different across:
- the original active ingredient/patent families
- method-of-use patents
- formulation/process patents
- regulatory exclusivities that can extend market protection beyond the first patent expiry

DrugPatentWatch is one of the quickest ways to identify the specific enzalutamide U.S. patents and their projected expiry dates by listing the patents involved and the likely “last protected” date. [1]

Can enzalutamide have different “expiration dates” depending on the patent?

Yes. Enzalutamide’s U.S. legal protections are not a single event. Different patents expire at different times, so “last generic entry” depends on which patents are still in force and any patent litigation or settlements affecting launch timing. DrugPatentWatch reflects these complexities by showing the patent-by-patent timeline. [1]

Where can I find the exact enzalutamide U.S. expiry dates?

Use DrugPatentWatch’s enzalutamide entry to see the listed U.S. patents and their projected expiration dates. [1]

Sources:
[1] https://www.drugpatentwatch.com/